R&D JP Morgan Week 2025 - Day 3 pharmaphorum's JPM Week live blog finishes strong with panels on AI, funding, and a conference wrap-up.
R&D JP Morgan Week 2025 - Day 2 On day 2 of pharmaphorum's JPM Week blog, we'll hear from leaders from the President of Novartis, a stacked industry panel on AI, and Dr Jill Biden.
News Lilly nets Scorpion cancer drug in $2.5bn licensing deal Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a breast cancer therapy being developed by Scorpion Therapeutics.
R&D JP Morgan Week 2025 - Day 1 On day 1 of JPM Week, join pharmaphorum as we hear about pharma's dealmaking plans and the changing pharma landscape.
News J&J agrees $14.6bn takeover of CNS biotech Intra-Cellular Johnson & Johnson has agreed to take over Intra-Cellular Therapies and its potential depression blockbuster Caplyta in a deal worth up to $14.6bn.
News GSK confirms plan to buy cancer firm IDRx for $1bn GSK confirms that it has agreed to buy US biotech IDRx and its KIT inhibitor for rare gastrointestinal tumours for $1bn upfront.
News EMA advisors say CSL's Tavneos should be pulled from sale Pressure is building on Amgen to withdraw rare disease therapy Tavneos, after the CHMP recommended its marketing authorisation by revoked in the EU.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
